Eli Lilly and Company (NYSE:LLY) Given Average Rating of “Moderate Buy” by Analysts

Shares of Eli Lilly and Company (NYSE:LLY) have earned a consensus rating of “Moderate Buy” from the thirty analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, twenty-three have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $1,216.5185.

A number of research firms have weighed in on LLY. Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 6th. Daiwa Securities Group boosted their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Finally, Argus boosted their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Monday, February 9th.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $7.54 on Tuesday, reaching $875.81. 464,098 shares of the stock were exchanged, compared to its average volume of 3,081,757. The stock has a market cap of $827.48 billion, a PE ratio of 38.16, a PEG ratio of 1.05 and a beta of 0.51. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The firm has a fifty day moving average price of $955.40 and a two-hundred day moving average price of $985.96.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 33.9 EPS for the current year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion, adding a first?in?class Type II JAK2 inhibitor (AJ1?11095) for myelofibrosis and strengthening its blood?cancer pipeline — a strategic push beyond the GLP?1 franchise. Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion
• Positive Sentiment: Analysts have reiterated bullish views after Lilly’s recent oncology deals (including Kelonia), with Barclays maintaining an Overweight stance and a lofty price target — signaling continued analyst conviction in longer?term growth and diversification. Analysts Reiterate Bullish Outlook on Eli Lilly and Company (LLY) Following Kelonia Acquisition
• Neutral Sentiment: Healthcare sector weakness is pressuring drug stocks broadly, creating headwinds for momentum names like Lilly even as fundamentals play out. Sector Update: Health Care Stocks Softer Late Afternoon
• Negative Sentiment: Competitor Boehringer Ingelheim reported up to 16.6% average weight loss in a late?stage obesity trial, underscoring intensifying competition in the obesity market that could pressure Lilly’s GLP?1 pricing and share over time. Boehringer?Zealand drug leads to 16.6% weight loss in late-stage trial
• Negative Sentiment: Data show Lilly’s oral GLP?1 (Foundayo) is trailing Novo Nordisk’s Wegovy tablet in prescription volumes at the same launch stage, raising near?term growth concerns for Lilly’s obesity rollout. GLP?1 pill race heats up as Wegovy tablet holds strong against Lilly rival
• Negative Sentiment: Leerink Partners cut its price target on LLY from $1,296 to $1,058 (still Outperform), a signal that some sell?side models are marking down near?term expectations despite longer?term conviction. Leerink Partners adjusts PT on Eli Lilly and Co to $1,058

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $25,000. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $25,000. Basso Capital Management L.P. acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $30,000. Miller Global Investments LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $33,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its position in shares of Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.